BR112016029864A2 - métodos e dispositivos para tratamento de desordens oculares posteriores. - Google Patents

métodos e dispositivos para tratamento de desordens oculares posteriores.

Info

Publication number
BR112016029864A2
BR112016029864A2 BR112016029864A BR112016029864A BR112016029864A2 BR 112016029864 A2 BR112016029864 A2 BR 112016029864A2 BR 112016029864 A BR112016029864 A BR 112016029864A BR 112016029864 A BR112016029864 A BR 112016029864A BR 112016029864 A2 BR112016029864 A2 BR 112016029864A2
Authority
BR
Brazil
Prior art keywords
methods
devices
ocular disorders
treating further
further ocular
Prior art date
Application number
BR112016029864A
Other languages
English (en)
Portuguese (pt)
Inventor
John Brooks Christopher
White Daniel
Noronha Glenn
Victor Andino Rafael
Patel Samirkumar
Original Assignee
Clearside Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clearside Biomedical Inc filed Critical Clearside Biomedical Inc
Publication of BR112016029864A2 publication Critical patent/BR112016029864A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Mycology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
BR112016029864A 2014-06-17 2015-06-17 métodos e dispositivos para tratamento de desordens oculares posteriores. BR112016029864A2 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201462013209P 2014-06-17 2014-06-17
US201462018148P 2014-06-27 2014-06-27
US201462063792P 2014-10-14 2014-10-14
US201562155367P 2015-04-30 2015-04-30
US201562156802P 2015-05-04 2015-05-04
PCT/US2015/036299 WO2015195842A1 (en) 2014-06-17 2015-06-17 Methods and devices for treating posterior ocular disorders

Publications (1)

Publication Number Publication Date
BR112016029864A2 true BR112016029864A2 (pt) 2017-08-22

Family

ID=54936084

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016029864A BR112016029864A2 (pt) 2014-06-17 2015-06-17 métodos e dispositivos para tratamento de desordens oculares posteriores.

Country Status (12)

Country Link
US (1) US20180042765A1 (https=)
EP (1) EP3157463A4 (https=)
JP (2) JP6774340B2 (https=)
KR (1) KR102511477B1 (https=)
CN (1) CN107072765A (https=)
AU (1) AU2015277133A1 (https=)
BR (1) BR112016029864A2 (https=)
CA (1) CA2952822A1 (https=)
IL (1) IL249602A0 (https=)
MX (1) MX2016016836A (https=)
RU (1) RU2017101236A (https=)
WO (1) WO2015195842A1 (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
JP5996544B2 (ja) 2010-10-15 2016-09-21 クリアサイド・バイオメディカル・インコーポレーテッドＣｌｅａｒｓｉｄｅ Ｂｉｏｍｅｄｉｃａｌ Ｉｎｃｏｒｐｏｒａｔｅｄ 眼球アクセス用装置
MX373894B (es) 2012-11-08 2020-07-09 Clearside Biomedical Inc Métodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.
BR112015027762A2 (pt) 2013-05-03 2017-08-29 Clearside Biomedical Inc Aparelho e métodos para injeção ocular
WO2014197317A1 (en) 2013-06-03 2014-12-11 Clearside Biomedical, Inc. Apparatus and methods for drug delivery using multiple reservoirs
BR112016018570B1 (pt) 2014-02-12 2022-08-30 Gyroscope Therapeutics Limited Aparelho para a liberação de agente terapêutico em um olho
US9925088B2 (en) 2014-06-06 2018-03-27 Janssen Biotech, Inc. Sub-retinal tangential needle catheter guide and introducer
US9949874B2 (en) 2014-06-06 2018-04-24 Janssen Biotech, Inc. Therapeutic agent delivery device with convergent lumen
EP3157598A4 (en) 2014-06-20 2018-05-16 Clearside Biomedical, Inc. Variable diameter cannula and methods for controlling insertion depth for medicament delivery
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US10219936B2 (en) 2014-09-11 2019-03-05 Orbit Biomedical Limited Therapeutic agent delivery device with advanceable cannula and needle
US10258502B2 (en) 2014-09-18 2019-04-16 Orbit Biomedical Limited Therapeutic agent delivery device
TWI806150B (zh) * 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
CA3010862A1 (en) * 2016-01-08 2017-07-13 Clearside Biomedical, Inc. Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics
CN109414577A (zh) * 2016-01-19 2019-03-01 皮博士研究所有限责任公司 用于制剂加工的装置及方法
US10390901B2 (en) 2016-02-10 2019-08-27 Clearside Biomedical, Inc. Ocular injection kit, packaging, and methods of use
US10478553B2 (en) 2016-03-09 2019-11-19 Orbit Biomedical Limited Apparatus for subretinal administration of therapeutic agent via a curved needle
EP3452165A1 (en) 2016-05-02 2019-03-13 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
US11000410B2 (en) 2016-06-17 2021-05-11 Gyroscope Therapeutics Limited Guide apparatus for tangential entry into suprachoroidal space
US10646374B2 (en) 2016-06-17 2020-05-12 Orbit Biomedical Limited Apparatus and method to form entry bleb for subretinal delivery of therapeutic agent
US10806629B2 (en) 2016-06-17 2020-10-20 Gyroscope Therapeutics Limited Injection device for subretinal delivery of therapeutic agent
IL305537B2 (en) 2016-08-12 2025-02-01 Clearside Biomedical Inc Devices and methods for adjusting the insertion depth of a needle for administering a drug
US11273072B2 (en) 2017-01-13 2022-03-15 Gyroscope Therapeutics Limited Suprachoroidal injection device
AU2018230478B2 (en) 2017-03-09 2025-01-23 Diamedica Inc. Dosage forms of tissue kallikrein 1
US11076984B2 (en) 2017-03-13 2021-08-03 Gyroscope Therapeutics Limited Method of performing subretinal drainage and agent delivery
US12090294B2 (en) 2017-05-02 2024-09-17 Georgia Tech Research Corporation Targeted drug delivery methods using a microneedle
WO2019133690A1 (en) * 2017-12-28 2019-07-04 Nichiban Co., Ltd. Transdermal drug delivery system and method for using same
US11724941B2 (en) 2018-02-15 2023-08-15 North Carolina State University Synthesis of micron and nanoscale carbon spheres and structures using hydrothemal carbonization
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
US20210046002A1 (en) * 2018-03-05 2021-02-18 Massachusetts Eye And Ear Infirmary Amelioration of autoimmune uveitis through blockade of csf1r
WO2019217678A1 (en) * 2018-05-09 2019-11-14 North Carolina State University Applicator for corneal therapeutics
US11039954B2 (en) * 2019-03-21 2021-06-22 Microoptx Inc. Implantable ocular drug delivery devices and methods
CN110009626A (zh) * 2019-04-11 2019-07-12 北京百度网讯科技有限公司 用于生成图像的方法和装置
CA3136814A1 (en) 2019-04-16 2020-10-22 Clearside Biomedical, Inc. Injectable triamcinolone formulations
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CA3171479A1 (en) * 2020-02-19 2021-08-26 Clearside Biomedical, Inc. Compositions comprising axitinib and methods of treating ocular disorders
KR102888055B1 (ko) * 2020-07-17 2025-11-21 에스에이치엘 메디컬 아게 마이크로 투여 장치 및 마이크로 투여 장치의 조립 방법
US20240000443A1 (en) * 2020-11-30 2024-01-04 Visionaire Products, Inc. Needle and collection device for ocular biopsy and methods of use
US20240000782A1 (en) * 2020-12-02 2024-01-04 Telios Pharma, Inc. Methods and compositions for treating an ophthalmic condition
JP2024500871A (ja) * 2020-12-17 2024-01-10 モビアス セラピューティクス， エルエルシー 注射装置および使用方法
CN113101502B (zh) * 2021-03-01 2023-01-17 李特 一种耳鼻喉科用治疗装置
CN113198003A (zh) * 2021-06-22 2021-08-03 万永年 一种用于皮肤损伤后预防萎缩性疤痕外用液及其制备方法
US20250177417A1 (en) * 2022-01-06 2025-06-05 Clearside Biomedical, Inc. Compositions and methods for treating macular edema associated with uveitis
TWI890114B (zh) * 2022-08-16 2025-07-11 美商奧伊斯特普安生物製藥公司 將藥物無菌地轉移至藥物遞送裝置的藥物轉移系統及方法
EP4590812A2 (en) * 2022-09-23 2025-07-30 Inoculus Ventures, LLC Dry eye treatment
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
AU2024287943A1 (en) * 2023-07-10 2026-01-22 Eden Ophthalmic Pte Ltd. Liposomal formulations of corticosteroids and uses thereof
WO2025179248A1 (en) * 2024-02-23 2025-08-28 Oculogenex Inc. Microneedle device for intraocular injections and methods of using the same
US20260015427A1 (en) 2024-06-25 2026-01-15 Kiniksa Pharmaceuticals, Gmbh Formulations of anti-interleukin 1 receptor 1 antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2951938B1 (ja) * 1998-03-19 1999-09-20 日本ケミカルリサーチ株式会社 薬剤溶解機構を内蔵した注射器
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
DE602005011928D1 (de) * 2004-01-20 2009-02-05 Allergan Inc Zusammensetzungen für die lokalisierte therapie des auges, vorzugsweise enthaltend triamcinolon-acetonid und hyaluronsäure
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US20070202186A1 (en) * 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
US8197435B2 (en) * 2006-05-02 2012-06-12 Emory University Methods and devices for drug delivery to ocular tissue using microneedle
US8802128B2 (en) * 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
EP2091482A2 (en) * 2006-12-01 2009-08-26 Allergan, Inc. Method for determining optimum intraocular locations for drug delivery systems
US8083759B2 (en) * 2007-11-02 2011-12-27 Refocus Ocular, Inc. Apparatuses and methods for forming incisions in ocular tissue
US8221353B2 (en) * 2008-10-21 2012-07-17 KMG Pharma, Inc Intravitreal injection device and system
EP3861969A1 (en) * 2010-08-05 2021-08-11 ForSight Vision4, Inc. Injector apparatus for drug delivery
US20120101475A1 (en) * 2010-10-21 2012-04-26 Meridian Medical Technologies, Inc. High Efficiency Auto-Injector
EP2578260A1 (en) * 2011-10-07 2013-04-10 Sanofi-Aventis Deutschland GmbH Apparatus for intraocular injection
MX373894B (es) * 2012-11-08 2020-07-09 Clearside Biomedical Inc Métodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.
CA2933900A1 (en) * 2013-12-20 2015-06-25 Georgia Tech Research Corporation Formulations and methods for targeted ocular delivery of therapeutic agents

Also Published As

Publication number Publication date
EP3157463A4 (en) 2018-02-21
WO2015195842A1 (en) 2015-12-23
KR20170039128A (ko) 2017-04-10
US20180042765A1 (en) 2018-02-15
MX2016016836A (es) 2017-07-27
AU2015277133A1 (en) 2017-02-02
KR102511477B1 (ko) 2023-03-16
JP2017524677A (ja) 2017-08-31
JP6774340B2 (ja) 2020-10-21
CN107072765A (zh) 2017-08-18
IL249602A0 (en) 2017-02-28
CA2952822A1 (en) 2015-12-23
RU2017101236A3 (https=) 2019-05-16
RU2017101236A (ru) 2018-07-17
EP3157463A1 (en) 2017-04-26
JP2020063236A (ja) 2020-04-23

Similar Documents

Publication Publication Date Title
BR112016029864A2 (pt) métodos e dispositivos para tratamento de desordens oculares posteriores.
IL283561B (en) Methods for treating ocular diseases
IL257252A (en) Methods of treating fgf21-associated disorders
IL279308A (en) Methods for the treatment of heptidine-mediated disorders
IL269371A (en) Treatment methods
BR112017007902A2 (pt) composições e métodos para o tratamento de distúrbios do sistema nervoso central.
IL269174A (en) Methods for treating complement-mediated diseases and disorders
PT3185957T (pt) Patisiran para utilização no tratamento de amoloidose mediada por transtirretina
HUE053485T2 (hu) Készítmények és eljárások meibom-mirigy diszfunkció kezelésére
HUE051488T2 (hu) Készítmények és eljárások központi idegrendszeri rendellenességek kezelésére
LT3261640T (lt) 5ht agonistai epilepsijos sutrikimų gydymui
BR112015002968A2 (pt) dispositivo para vestir e método para fabricar o mesmo
IL251215B (en) Cannabinoid composition and method for treating pain
BR112016026939A2 (pt) aparelho e método.
BR112016021682A2 (pt) cenicriviroc para o tratamento da fibrose
ZA201700416B (en) Methods for treating or preventing ophthalmological conditions
DK3231444T3 (da) Ny behandling
BR112016016792A2 (pt) Aparelho para tratamento de vestuário
HUE050944T2 (hu) Kezelési eljárás tradipitant alkalmazásával
HUE049518T2 (hu) Készítmények és eljárások a szem megbetegedéseinek kezelésére és diagnosztizálására
DK3393579T3 (da) Øjenbehandlingssystem
BR112016022976A2 (pt) Métodos para o tratamento de hcv
PT3215157T (pt) Apilimod para utilização no tratamento de melanoma
ES2893126T8 (es) Métodos de tratamiento de afecciones oculares
BR112016029236A2 (pt) métodos para tratar prurido.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements